JPRN-UMIN000027542
Completed
未知
Special drug use results surveillance for the use of SIMPONI in ulcerative colitis - SMP4
Conditionsulcerative colitis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ulcerative colitis
- Sponsor
- Janssen Pharmaceutical K.K.
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with a history of use of Golimumab (active ingredient of this product)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
Completed
Not Applicable
Special Drug Use-results Surveillance for long term administration in adult (18 years and older) of CONCERTA, 18mg/ 27mg/ 36mg TabletsAttention deficit hyperactivity disorder (ADHD)JPRN-UMIN000015900Janssen Pharmaceutical K.K500
Completed
Not Applicable
Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringeSchizophreniaJPRN-UMIN000018665Janssen Pharmaceutical K.K.1,050
Recruiting
Not Applicable
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90